Internal Reference Number: FOI_8026
Date Request Received: 02/07/2024 00:00:00
Date Request Replied To: 15/07/2024 00:00:00
This response was sent via: By Email
Request Summary: Haematology and Immunoglobulin Treatments
Request Category: Companies
| Question Number 1: In the past 3 months, how many patients have received the following treatments (for any disease): • Berinert (Human C1-esterase inhibitor) • Cinryze (Human C1-esterase inhibitor) • Firazyr (Icatibant) • Icatibant - any brand except Firazyr • Orladeyo (Berotralstat) • Ruconest (Recombinant human C1-esterase inhibitor) • Takhzyro (Lanadelumab) | |
| Answer To Question 1: Please see attached response to Q1 To accompany this answer to question 1 please also see the documents listed below:  FOI 8026 Question 1 complete.pdf | |
| Question Number 2: In the past 3 months, how many patients have received the following immunoglobulin treatments (for any disease): • Cutaquig • Cuvitru • Gammagard • Gammanorm • Hizentra • Hyqvia • Intratect • Iqymune • Kiovig • Privigen • Octagam • Panzyga • Subgam • Any other normal immunoglobulin | |
| Answer To Question 2: Please see attached document for response to Q2 To accompany this answer to question 2 please also see the documents listed below: FOI 8026 Question 2 complete.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
